Objective-Thrombosis is a leading cause of morbidity and mortality worldwide. Current diagnostic strategies rely on imaging modalities that are specific for distinct vascular territories, but a thrombus-specific whole-body imaging approach is still missing. Moreover, imaging techniques to assess thrombus composition are underdeveloped, although therapeutic strategies may benefit from such technology. Therefore, our goal was to test whether positron emission tomography (PET) with the fibrin-binding probe 64 Cu-FBP8 allows multisite thrombus detection and fibrin content estimation. Approach and Results-Thrombosis was induced in Sprague-Dawley rats (n=32) by ferric chloride application on both carotid artery and femoral vein. 64 Cu-FBP8-PET/CT imaging was performed 1, 3, or 7 days after thrombosis to detect thrombus location and to evaluate age-dependent changes in target uptake. Ex vivo biodistribution, autoradiography, and histopathology were performed to validate imaging results. Arterial and venous thrombi were localized on fused PET/CT images with high accuracy (97.6%; 95% confidence interval, 92-100). A single whole-body PET/MR imaging session was sufficient to reveal the location of both arterial and venous thrombi after 64 Cu-FBP8 administration. PET imaging showed that probe uptake was greater in younger clots than in older ones for both arterial and venous thrombosis (P<0.0001). Quantitative histopathology revealed an age-dependent reduction of thrombus fibrin content (P<0.001), consistent with PET results. Biodistribution and autoradiography further confirmed the imaging findings.
T hrombosis is often the underlying cause of major cardiovascular diseases, including heart attack, stroke, and venous thromboembolism, which are leading causes of morbidity and mortality. 1 Current imaging modalities have good sensitivity and specificity, and have been accepted as gold standards for thrombus detection depending on the anatomic location. Particularly, transesophageal echocardiography and contrast-enhanced magnetic resonance imaging (MRI) are used to detect thrombi in the cardiac chambers, 2 Doppler ultrasound has high sensitivity for deep vein thrombosis, 3 and computed tomography (CT) is the gold standard in the diagnosis of pulmonary embolism 4 and is used to detect the early signs of stroke. 5 However, thrombus imaging would benefit from a whole-body approach capable of detecting multisite thrombi instead of several examinations, especially for those cardiovascular events (eg, thromboembolism) where the identification of both culprit embolus and source thrombus is necessary. Moreover, thrombus detection often relies on anatomic and mechanical vascular abnormalities or on blood flow deficit rather than directly imaging the target, which may negatively affect the specificity of detection. Furthermore, none of these modalities are informative about the composition of the thrombus, although therapeutic strategies may benefit from such information. 6, 7 See cover image Direct targeting of the thrombus components using molecular imaging offers instead a noninvasive solution with high sensitivity and specificity, as well as potential whole-body applications. 8, 9 Several components of the coagulation cascade have been targeted to date with molecular probes, including some specific and abundant thrombus constituents as activated platelets 10, 11 and fibrin. 12, 13 In particular, fibrin is an ideal target for molecular imaging of thrombosis because it is present at high concentrations in both venous and arterial clots but not in circulating blood, resulting in potential high sensitivity and specificity of detection. 14 We recently evaluated several positron emission tomography (PET) probes for noninvasive thrombus detection [15] [16] [17] [18] [19] based on fibrin-targeting peptides with high specificity for fibrin over fibrinogen and other plasma proteins. 20, 21 The fibrin-binding probe 64 Cu-FBP8 emerged as the best candidate for further translation because of its high target affinity, fast blood clearance, and high metabolic stability.
Here, we aim to assess the feasibility of 64 Cu-FBP8-PET imaging for whole-body thrombus detection in both the venous and arterial circulation at different stages of thrombus evolution after a single administration of probe. Moreover, we also tested whether 64 Cu-FBP8-PET could inform thrombus composition by noninvasive evaluation of fibrin content.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Detection of Arterial and Venous Thrombi With 64
Cu-FBP8-PET
Thrombi were generated in the common carotid artery and femoral vein of 32 Sprague-Dawley rats using the ferric chloride model, 22 and thrombus location (right versus left) was kept undisclosed until the end of the study to assess in a blinded fashion the accuracy of 64 Cu-FBP8-PET imaging. Contralateral incisions were performed to create a sham surgical wound, hiding the actual location of the clot. At 1, 3, or 7 days after thrombus induction, rats were imaged according to the scheme depicted in Figure 1 . Sequential PET scans of the hindlimbs and the neck region revealed the presence of isolated hot-spots in every animal. The localization of the radioactivity in PET images was suggestive of the common carotid artery and femoral vein visualized with CT angiography. Fused PET/CT images confirmed that the isolated hot-spots were located in the thrombosed vessels. Some radioactivity was detected at the surgical wound and the excretory organs, as previously reported. [15] [16] [17] [18] [19] Blinded analysis of the accuracy of 64 Cu-FBP8-PET imaging to detect the thrombus location was performed by 2 independent readers on a total of 21 animals. One reader correctly detected the location of 40 thrombi of 42 (1 day, 14/14; 3 days, 14/14; and 7 days, 12/14), whereas the other correctly detected the location of all clots (42/42). The mean overall accuracy was 97.6% (82/84), with an exact 95% confidence interval ranging from 0.916 to 0.997.
To further demonstrate that 64 Cu-FBP8-PET is suitable for multisite thrombus detection with a single whole-body scan, we imaged a small cohort of rats in a clinical PET/MR scanner 1 day after thrombosis, as previously described. 15, 16 Rats were imaged for 60 minutes starting 1 hour after 64 Cu-FBP8 injection ( Figure 2 ). The location of both arterial and venous thrombi was clearly identified in this wide field of view after Cu-FBP8. Background activity was only detected in the liver, surgical wounds, and excretory organs.
Cu-FBP8 Uptake in Arterial and Venous Thrombi Depends on Thrombus Age
64 Cu-FBP8-PET imaging revealed that the radioactive signal for both arterial and venous thrombi was dependent on thrombus age. Signal intensity was the greatest in 1-day old thrombi and gradually declined with thrombus age, with a statistically significant difference among the 3 groups (P<0.0001, 1-way ANOVA; Figure 3 ). Particularly, we observed 0.65±0.19 %ID/cc±SD (1 day), 0.35±0.16 (3 days), and 0.06±0.02 (7 days) for the arterial clots, and 0.55±0.15 %ID/cc±SD (1 day), 0.36±0.05 (3 days), and 0.12±0.04 (7 days) for the venous thrombi. Contralateral carotid artery and femoral vein did not show any radioactive signal that could suggest the presence of a thrombus. Some activity was detected at the surgical wound, excretory organs, and genital area, the latter consistent with urine contamination. The high thrombus uptake combined with the low off-target background resulted in high target/background ratios. For the arterial thrombus, we found 20-to 30-fold at 1 day after surgery, 10-to 20-fold at 3 days, and 2-to 4-fold differences at 7 days, whereas for the venous clots, we observed 10-to 20-fold, 5-to 10-fold, and 2-to 4-fold differences at 1, 3, and 7 days after thrombosis, respectively. Because the arteries were imaged >1 hour after the veins, and because 64 Cu-FBP8 progressively clears from background tissues but shows steady levels at the target site, 18 this difference in target/background ratios between arterial and venous thrombi is expected based on the timing of the imaging.
Ex Vivo Biodistribution, Autoradiography, and Histopathology
Animals were euthanized at the end of the imaging experiments, and tissues were harvested and processed for biodistribution, autoradiography, and histopathology. The presence and the location (left versus right) of the thrombi in the carotid artery and femoral vein were confirmed in every animal. Biodistribution analysis showed that probe uptake was highest in the younger thrombi for both arterial and venous clots ( Figure 4 ). In particular, the uptake of the arterial thrombi was 1.17±0.39 %ID/g±SD at 1 day, 0.66±0.36 at 3 days, and 0.20±0.19 at 7 days, whereas the activity at the level of the venous thrombi was 1.46±0.76 %ID/g±SD at 1 day, 0.96±0.65 at 3 days, and 0.21±0.10 at 7 days. Pearson's analysis showed a positive correlation between the probe uptake detected with γ-counting and PET quantification, a further validation of the imaging findings. Ex vivo autoradiography showed results comparable with PET imaging and γ-counting. A hyperintense region was detected in the thrombosed vessels, but not contralaterally. Autoradiography performed on histological slices confirmed the high activity of ipsilateral vessels, corresponding to the hematoxylin and eosin-stained thrombus, and low activity in contralateral arteries and veins. Quantitative assessments revealed high ipsilateral/contralateral activity ratios for arterial and venous thrombi, with a trend comparable with PET imaging and biodistribution. We observed higher ipsilateral/ contralateral ratios for the younger thrombi (artery: 15-fold at 1 day and 10-fold at 3 days; vein: 35-fold at 1 day and 15-fold at 3 days) than for the older ones (artery: 3-fold at 7 days; vein: 5-fold at 7 days).
Histopathology revealed time-dependent changes of thrombus size and composition for both arterial and venous clots (P<0.001, 1-way ANOVA; Figure 5 ). Martius Scarlet Blue 23 staining showed that thrombi were conspicuous at 1 and 3 days after surgery, whereas at 7 days, the clots comprised a lesser extent of the vessel. Fibrin was a major constituent of both arterial and venous thrombi, confirmed by histochemical and immunofluorescence stainings. Younger thrombi (1 and 3 days) were rich in fibrin (purple-red) and erythrocytes (yellow), whereas some collagen fibers (blue) were also present at 7 days. Color segmentation was performed on Martius Scarlet Blue-stained sections to quantitatively assess the thrombus composition. [24] [25] [26] The fibrin content peaked at 1 day post thrombosis for both carotid artery and femoral vein and gradually decreased over time along with the thrombus size. At 7 days after thrombosis, the fibrin content in venous thrombi was greater than in arterial clots, consistent with the difference 
Discussion
The aim of this study was to assess the feasibility and potential of 64 Cu-FBP8-PET for whole-body thrombus detection and fibrin content estimation. We recently demonstrated that 64 Cu-FBP8 has high target uptake, rapid systemic clearance, and low off-target retention in an animal model of hyperacute mural arterial thrombosis. 18 In the present work, we extended our findings to other clinically relevant time points by imaging the acute and subacute stages of thrombus evolution in both arteries and veins. We first showed that 64 Cu-FBP8-PET is suitable for imaging multiple thrombi in different vascular territories and anatomic locations (neck and hindlimbs), with an overall accuracy >97%. The high probe uptake, combined with the fast off-target washout, allowed detection of arterial and venous thrombi with high target/background ratios. Then, we assessed whether 64 Cu-FBP8-PET can provide insights on thrombus age and composition by evaluation of fibrin content. Our findings showed that probe uptake was higher for the younger clots and lower for the older ones and that such agedependent uptake was consistent with the amount of fibrin in these thrombi. Taken together, these results provide a proofof-concept for a new, sensitive approach based on PET imaging for whole-body thrombus detection and to noninvasively assess changes in thrombus composition by directly targeting its main component: fibrin.
Despite the recent advances in noninvasive thrombus detection, current imaging modalities still have some limitations that challenge both diagnosis and therapy monitoring. A main diagnostic drawback is the absence of a single-session approach with high sensitivity and specificity to detect thrombosis in different anatomic locations. In fact, sensitivity and specificity of current imaging modalities depend on Cu-FBP8 showing age-dependent decrease in arterial (A) and venous (B) thrombus uptake. No uptake was detected in the contralateral vessels (contra). PET quantification reveals statistically significant differences in thrombus uptake among groups and high target/background tissue ratios for both arterial (C) and venous (D) thrombi. Contra indicates contralateral; and ipsi, ipsilateral. Yellow arrow indicates thrombus; red thin arrow, contralateral vessel; blue arrowheads, surgical wound; and green arrowheads, urine. Error bars are SEM. ***P<0.001 and **P<0.01, 1-way ANOVA followed by Tukey post hoc test. n=7 per group. the anatomic location of the thrombus. [2] [3] [4] [5] However, in the case of thromboembolism, both diagnosis and therapeutic strategy would benefit from a single approach with whole-body detection capabilities to reveal the location of the culprit embolus (eg, middle cerebral artery in case of stroke, pulmonary artery in case of pulmonary embolism) and the source thrombus (eg, atherosclerotic carotid plaque, aortic arch, left atrial thrombus, deep vein thrombosis). Indeed, a potential application for 64 Cu-FBP8-PET is secondary stroke prevention. The diagnosis of stroke pathogenesisis crucial for secondary prevention because the risk of recurrences is associated with the underlying pathology. 27 Current stroke diagnostic workup includes ultrasonography, transesophageal echocardiography, MR angiography, and CT angiography to detect common embolic sources (eg, aortic arch and intra/extracranial atheroma, atrial thrombi), resulting in a time consuming and expensive process that can delay therapeutic intervention. 28 Despite these different diagnostic tools, a third of ischemic strokes are classified as cryptogenic (ie, the source thrombus is unknown). 29 A wholebody approach would be beneficial in this large population. Earlier work with 64 Cu-FBP7, a close analog of 64 Cu-FBP8, detected carotid thrombi and intra/extracranial emboli with high target/background ratios, and we anticipate similar efficacy with 64 Cu-FBP8 17 . Therefore, if translated to a clinical setting, 64 Cu-FBP8-PET may help identify the location of both the culprit embolus (eg, middle cerebral artery) and the source thrombus (eg, carotid artery, aortic arch) in stroke patients.
Thrombus evolution is a dynamic process, and changes in fibrin content can affect clot stability. Human thrombi are characterized by platelets and fibrin in the early phase, whereas smooth muscle cells, proteoglycans, and collagen are main constituents of healing clots. 30, 31 Fresh clots are usually softer, unstable, and are more likely to be lysed than mature, organized thrombi. 32 Therefore, noninvasive assessment of clot composition can be useful for thrombus staging and to facilitate therapeutic choices (eg, thrombolysis versus thrombectomy). 6, 7 Several attempts have been made to characterize thrombus composition using noninvasive imaging. Ultrasound elastography has shown thrombus staging capabilities ex vivo, 33 but its feasibility still needs to be addressed in vivo. Changes in T 1 relaxation time, magnetization transfer, and diffusion-weighted MRI have been associated with iron metabolism and protein turnover of venous thrombi, showing diagnostic potential to assess thrombus age and predict successful clot lysis. 24, 25 However, noncontrast MRI offers limited target sensitivity and specificity, and therefore detecting small thrombotic events may be challenging especially for wholebody applications. Molecular MRI using the fibrin-binding probe EP-2104R has shown good correlation with fibrin thrombus content. 26 However, molecular MRI requires pre and postcontrast imaging sessions, which can delay the diagnostic workflow. Moreover, previous experience with EP-2104R in patients with thrombosis revealed that the clots appear more conspicuous at later time points after injection (24 hours), 34 which may complicate the analysis of pre and postprobe images and further delay decision making and treatment. Scintigraphy with the 99m Technetium-labeled activated platelets, inhibitor DPM-444 10 and 99m Technetium-rtPA 35 have shown good feasibility identifying fresh clots over organized thrombi, but at the same time the low efficacy in detecting mature clots reduced their clinical applications. Fluorodeoxyglucose-PET has been recently used to stage thrombosis by imaging neutrophilic infiltration in fresh venous thrombi. 36 However, fluorodeoxyglucose uptake is also increased in other pathologies associated with high cellularity and hypermetabolism (eg, cancer, chronic inflammatory conditions), which may limit the specificity of this imaging approach. The findings shown here demonstrate that 64 Cu-FBP8-PET can detect differences in fibrin content in both arterial and venous clots, even when thrombi were small and fibrin levels low (ie, 7-day old thrombi). Because the high target specificity of molecular imaging and the great sensitivity and absolute quantification capabilities of PET, thrombus imaging with 64 Cu-FBP8 may overcome the shortcomings of previous imaging modalities and thus provide a novel approach for whole-body clot detection and fibrin content estimation.
This work has some limitations, including the small sample size. We tested our hypothesis in animal models that only partially mimic the human pathology; therefore, our results need to be validated in clinical settings. Moreover, this approach may not be suitable for diagnosis of thrombosis in the emergency department, where minutes of delay negatively affect the clinical outcome. However, 64 Cu-FBP8-PET may be beneficial when the life-threatening culprit is under control, but the source thrombus is still unknown and the risk of recurrence is high. In these circumstances, a thrombus imaging approach with whole-body clot detection capabilities may provide useful insight for both diagnosis (eg, etiologic assessment) and intervention. PET imaging has higher costs compared with other modalities and exposes the patient to ionizing radiation. However, the high sensitivity of PET allows using micrograms of tracer compared with other contrast-based imaging modalities where grams of probe are required (eg, MRI), thus reducing potential chemical toxicity. Despite the relatively long half-life of 64 Cu (12.7 hours), the rapid whole-body clearance and low retention of 64 Cu-FBP8 suggest that radiogenic adverse effects should not limit its clinical translation, 18 and recent radiation dosimetry studies in rats support this conclusion. 37 Moreover, the longer half-life may allow synthesis of the molecular probe in advance, and even on demand shipment to remote sites far from a cyclotron. Finally, because of its straightforward radiolabeling procedure, 64 Cu-FBP8 is also amenable to kit formulation which may further facilitate bench-to-bedside translation.
Conclusions
64
Cu-FBP8-PET is a feasible approach for whole-body thrombus detection and for noninvasive evaluation of fibrin content and represents a novel and valuable diagnostic strategy for translation in clinical imaging of thrombosis.
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